2 Top Diabetes Stocks to Buy Right Now
In 2019, the diabetes treatment and drug market in the United States reached a landmark valuation of over $15 billion. By 2025, the total valuation of the U.S. and European diabetes treatment markets is expected to top $16 billion and $10 billion, respectively. If you have been thinking about investing in diabetes stocks, there are a few in particular that present particularly attractive buying opportunities at the moment.
Since its founding in 1876, Eli Lilly (NYSE: LLY) has remained a kingpin in the pharmaceutical industry, and it boasts a variety of insulins and treatments for diabetes in its product offerings. A serious competitor to Eli Lilly's star power is the world's leader in the diabetes market, Danish pharmaceutical company Novo Nordisk (NYSE: NVO). Here's why you may want to consider adding one or both of these diabetes stocks to your investment portfolio.
Image Source: Getty Images.
Source Fool.com
